Cibinitide ARA-290 16mg

Native erythropoietin activates the classical homodimeric EPO receptor to drive erythropoiesis (red blood cell production) in addition to other downstream effects.

Cibinitide was engineered to selectively engage the innate repair receptor (IRR) — a distinct heterodimeric complex of the EPO receptor and the common beta receptor subunit (CD131) — without activating the homodimeric EPO receptor pathway responsible for erythropoietic effects.

Research distinguishing these two signalling outcomes typically uses hematocrit or reticulocyte count as a readout for erythropoietic activity alongside IRR-specific signalling markers, to confirm selective IRR engagement without off-target erythropoietic stimulation.

Cell lines expressing the IRR complex (EPO receptor plus CD131) are used in receptor engagement and downstream signalling assays, typically measuring activation of JAK2/STAT5 or other cytoprotective signalling intermediates following cibinitide exposure, compared against cell lines expressing only the classical homodimeric EPO receptor to confirm receptor-complex-dependent selectivity. Inflammatory pathway readouts — such as NF-κB activation status or downstream cytokine production — are also used in models examining cibinitide's reported anti-inflammatory signalling effects.

Rodent models of tissue injury and inflammatory challenge — including peripheral nerve injury, ischemia-reperfusion injury models, and inflammatory pain models — have been used to study cibinitide's effects on cytoprotective and anti-inflammatory signalling pathways downstream of IRR activation. These studies typically combine behavioral or functional injury-recovery endpoints with tissue-level markers of inflammation and cell survival to characterise the peptide's pathway-specific effects in an intact physiological system.